Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV
  • CME

Learn guideline-based patient-specific HBV management recommendations using this Interactive Decision Support Tool.
Kosh Agarwal, MD
Paul Y. Kwo, MD
Grace LH Wong, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: March 21, 2019 Expiration: March 20, 2022

Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV


This Interactive Decision Support Tool provides HBV management recommendations from US, European, or Asian Pacific guidelines based on the specific patient characteristics you enter. (See “About This Tool” in the Table of Contents for more information.)

After viewing the recommendations from the guideline of your choice, you will have an opportunity to tell us whether they either confirmed or changed your management choices and leave any comments about this tool.

The current tool was created in January 2019 and reflects the guidelines at that time.

Interactive Decision Support Tool
Hep B Consult: Treat or Monitor


Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for monitoring or treating individuals with chronic HBV infection. The information provided is based on the AASLD, EASL, and APASL guideline recommendations and expert guidance of Kosh Agarwal, BMed, Sci(Hons), MD, FRCP; Paul Y. Kwo, MD; and Grace LH Wong, MBChB(Hons), MD, FRCP(Lond, Edin), FHKCP, FHKAM(Medicine).

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.
© 2019 Clinical Care Options, LLC. All rights reserved.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify whether each individual patient with chronic HBV infection is currently a candidate for treatment
  • Appropriately monitor untreated HBV patients to ensure prompt identification of change in their status such that treatment becomes appropriate
  • Select an appropriate treatment regimen for each patient based on individualized application of clinical practice guidelines

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Kosh Agarwal, MD

Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
King's College Hospital NHS Foundation Trust
London, United Kingdom

Kosh Agarwal, MD, has disclosed that he has received funds for research support from Gilead Sciences and Merck Sharp & Dohme and consulting fees from Arbutus, Gilead Sciences, and Vir Biotechnology.
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received funds for research support from Assembly, Bristol-Myers Squibb, and Gilead Sciences; has served as an advisory board member for AbbVie, Arrowhead, Bristol-Myers Squibb, Gilead Sciences, and Quest; and has served as a data and safety monitoring board member for Johnson & Johnson.
Grace LH Wong, MD

Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong

Grace LH Wong, MD, has disclosed that she has received funds for research support from Gilead Sciences; consulting fees from Gilead Sciences and Janssen; and fees for non-CME/CE services from Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche.


Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no real or apparent conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who provide care for patients with HBV infection.


The goal of this activity is to improve participants’ competence in identifying candidates for HBV therapy and monitoring and managing individuals with HBV infection.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 21, 2019, through March 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.

You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Audio commentary from Dr. Robert Brown on when to treat chronic hepatitis B, what drugs to use, and when to consider stopping HBV therapy.

Robert S. Brown, Jr., MD, MPH Released: August 14, 2019

CME/CE/CPE-certified video on current and emerging treatment strategies for chronic hepatitis B with Paul Y. Kwo, MD, from CCO Hepatitis Annual Meeting

Ira M. Jacobson, MD
Program Director
Paul Y. Kwo, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.7 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: June 27, 2019 Expiration: June 26, 2020

Downloadable slides from CCO: Dr. Ira Jacobson debates whether to treat immune-tolerant chronic hepatitis B and if ALT ≥ 2 x ULN should define treatment candidacy

Ira M. Jacobson, MD Released: June 21, 2019

Expert overview of recommendations on the management of patients with HBV infection.

Stefan Zeuzem, MD
Program Director
Harry L. A. Janssen, MD, PhD Milan J. Sonneveld, MD, PhD, MSc
Released: June 17, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

In collaboration with
Supported by an educational grant from
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?